Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

r extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C- IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1- 800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; legal matters, including the ultimate outcome of the FTC litigation or the amount of time it will take for the FTC litigation to be resolved; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... With the ability to record continuously at over 500 ... minutes, Fastec Imaging has brought the same ease-of-use of today’s ... a high speed camera that can be used as simply ... proclaims Matt Kearney, VP of Sales for Fastec Imaging. ... simplify the traditionally complicated workflow of a high speed camera. ...
(Date:7/23/2014)... Cambridge, MA (PRWEB) July 23, 2014 ... provider of innovative and comprehensive consultancy and pharma ... Research Excellence and Safety (ACRES) , a non-profit ... worldwide to build and maintain a global system ... strategic alliance collaboration to improve the expertise of ...
(Date:7/22/2014)... of Standards and Technology (NIST) and California Institute ... for an atomic clock that is based on ... The microcomb clock, featured on the cover of ... Optica ,* is the first demonstration of all-optical ... of optical frequencies to lower microwave frequencies. (Optical ...
(Date:7/22/2014)... York (PRWEB) July 22, 2014 Nuclear ... The heat produced by controlled fission chain reaction in ... steam pressure is used to drive a power- generating ... 19% of the world’s total electricity production. Nuclear reactor ... several under construction, planned and proposed nuclear reactor projects. ...
Breaking Biology Technology:Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3'Comb on a chip' powers new NIST/Caltech atomic clock design 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that results from a second Phase II ... Annual Conference on Vaccine Research, being held in Baltimore, ... the National Foundation of Infectious Diseases.David P. Wright, President ...
... 28 Techne Corporation (Nasdaq: TECH ) announced ... dividend of $0.25 per share for the quarter ended March ... 22, 2009 to all common shareholders of record on May ... the Board of Directors on a quarterly basis.Techne,s Board of ...
... for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand ... 28 Cepheid (Nasdaq: CPHD ) today ... Patient Management in the Era of Rapid Diagnostics ," ... Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking ...
Cached Biology Technology:PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 3Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 4Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 5
(Date:7/23/2014)... As of 2015, Springer will publish the International ... official journal of the Taiwan Fuzzy Systems Association (TFSA). ... global visibility in the area of fuzzy research., The ... to presenting high-quality papers that deal with the theory, ... gray systems and extension theory systems ranging from hardware ...
(Date:7/23/2014)... , July 23, 2014   MedNet ... specializing in clinical study management systems, is pleased ... a proven life sciences industry executive with over ... Operating Officer (COO).  Clareece will be responsible for ... growth, operational efficiency and quality product/service delivery.  ...
(Date:7/23/2014)... Streptococcus mutans , one of the principal bacteria ... in its genetic material over time, possibly coinciding ... humanity. This is highlighted in a study ... (UAB) and the Laboratorio Nacional de Genmica para ... in Mexico who, for the first time, have ...
Breaking Biology News(10 mins):MedNet Appoints Clareece West As Chief Operating Officer 2Ancient genetic material from caries bacterium obtained for the first time 2
... (NASDAQ: MASI ) today announced that its management ... Health Care Conference at the New York Palace Hotel in New York ... A live audiocast of the presentation will be available on ... the audiocast will be available following the live presentation. ...
... have suggested that climate change is causing additional stress to ... consider a significant reduction, or in some places elimination of ... growing degradation of grazing lands could be mitigated if large ... lands became free of use by livestock and "feral ungulates" ...
... CINCINNATIA University of Cincinnati (UC) Cancer Institute lung cancer ... be isolatedand then grownin a preclinical model, offering a ... target stem cells. John C. Morris, MD, ... 13, 2012, issue of PLOS One , a ...
Cached Biology News:Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 2Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 3Climate change increases stress, need for restoration on grazed public lands 2Climate change increases stress, need for restoration on grazed public lands 3Stem cell finding could advance immunotherapy for lung cancer 2